RxDoctor Payments Data

Kelly Kinsey

Psychiatric/Mental Health · Monroe, MINPI 1215344684

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 295 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,318, 6.3 times the $367 reported in 2021. Among psychiatric/mental health clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,955in general payments, 2019–2025

Across 295 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$801
  • AbbVie$775
  • Teva Pharmaceuticals USA, Inc.$705
  • Alkermes, Inc.$450
  • Neurocrine Biosciences, Inc.$439
  • plus $2K from 11 others

What the payments were for

  • Food & beverage$5,71396%
  • Education$2424%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,955 in reported general payments places this provider in the 90th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$18,845
Medicare patients
40
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate65$596,187
Invega SustennaPaliperidone Palmitate144$435,551
VraylarCariprazine Hcl120$166,957
Abilify MaintenaAripiprazole59$162,213
Invega TrinzaPaliperidone Palmitate13$138,949
CaplytaLumateperone Tosylate76$120,832
RexultiBrexpiprazole88$120,804
Austedo XrDeutetrabenazine22$116,520
AristadaAripiprazole Lauroxil40$115,656
Risperdal ConstaRisperidone Microspheres43$92,392
TrintellixVortioxetine Hydrobromide61$29,087
SecuadoAsenapine20$28,127
AuvelityDextromethorphan Hbr/Bupropion16$16,758
Aripiprazole288$15,838
Lurasidone Hcl124$14,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$224$666,892200 claims
Neurocrine Biosciences, Inc.Ingrezza$439$596,18765 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$1,028$283,017147 claims
AbbVieVraylar$775$166,957120 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$801$120,83276 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$705$116,52022 claims
Alkermes, Inc.Aristada$450$115,65640 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$116$29,08761 claims
Axsome Therapeutics, Inc.Auvelity$323$16,75816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Monroe

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →